BMS, AstraZeneca win European nod for Onglyza with insulin in Type II diabetes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and its partner AstraZeneca won approval from the European Commission on 28 November for their dipeptidyl peptidase-4 inhibitor Onglyza (saxagliptin) as a treatment in combination with insulin, with or without metformin, to improve glycaemic control in adults with Type II diabetes.